Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 13.6h

Persistency of Discharge Regimen by Follow-up Period, 2004 to 2008

Recipients with Heart-Lung Transplants

  Year of Transplant
2004 2005 2006 2007 2008
Discharge Regimen (w/ or w/o Steroid Use) CyA+Aza At Discharge (N) 5 10 3 - 1
At Discharge (%) 100.0% 100.0% 100.0% - 100.0%
1 Year PostTx (%) 60.0% 90.0% 66.7% - -
2 Years PostTx (%) 20.0% 20.0% 0.0% - -
3 Years PostTx (%) 20.0% 20.0% 0.0% - -
CyA+MMF At Discharge (N) 5 3 2 1 1
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 20.0% 100.0% 50.0% 100.0% 100.0%
2 Years PostTx (%) 20.0% 66.7% 0.0% - -
3 Years PostTx (%) 20.0% 66.7% 0.0% - -
Tac+Aza At Discharge (N) 5 2 1 3 -
At Discharge (%) 100.0% 100.0% 100.0% 100.0% -
1 Year PostTx (%) 60.0% 100.0% 100.0% 66.7% -
2 Years PostTx (%) 40.0% 100.0% 0.0% - -
3 Years PostTx (%) 40.0% 50.0% 0.0% - -
Tac+MMF At Discharge (N) 11 12 15 19 18
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 81.8% 58.3% 66.7% 73.7% 77.4%
2 Years PostTx (%) 54.5% 33.3% 53.3% 55.3% 51.6%
3 Years PostTx (%) 54.5% 33.3% 33.3% 55.3% -
Tac+Siro At Discharge (N) 1 - - - -
At Discharge (%) 100.0% - - - -
1 Year PostTx (%) 100.0% - - - -
2 Years PostTx (%) 100.0% - - - -
3 Years PostTx (%) 100.0% - - - -


Source: OPTN/SRTR Data as of October 1, 2010.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen

(CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.&

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.